Diabetes, antihyperglycemic medications and cancer risk: smoke or fire?
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this review article is to discuss the epidemiological links between diabetes and cancer; the potential biological mechanisms linking diabetes, obesity and cancer; the risk of cancer associated with antidiabetic medications. METHODS: The data discussed in this review were obtained from the American Association of Clinical Endocrinologists Consensus Conference on Diabetes and Cancer, held in New York, NY, USA, September 2012. RESULTS: The results of these studies demonstrate a significant association between diabetes and the risk of multiple cancers, including hepatocellular, pancreatic, endometrial, colorectal, breast, kidney, bladder, gastric, and ovarian cancer, non-Hodgkin lymphoma, T cell lymphoma and leukemia. There are multiple potential biological mechanisms that may link type 2 diabetes, obesity and cancer. Insulin resistance and hyperinsulinemia may lead to direct activation of the insulin receptors on tumor cells and promote tumor growth. Other potential mechanisms include increased circulating, local or bioavailable insulin-like growth factor 1, hyperglycemia, dyslipidemia, increased circulating or local estrogen, adipokines and direct and indirect effects of inflammatory cytokines. Epidemiological studies have had conflicting results regarding the associations between various classes of antidiabetic medication and cancer development. Animal studies have demonstrated increased tumor growth with certain medications, but their relevance to humans is uncertain. Metformin may, however, have protective effects on cancer development and may improve survival in patients with cancer. CONCLUSION: We describe the current understanding of the links among diabetes, antidiabetic medication and cancer risk. We highlight some of the issues that should be addressed in the future to prevent cancer development and death in those with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Reeves, G. K., Pirie, K., Beral, V., Green, J., Spencer, E., & Bull, D. (2007) · BMJ · doi:10.1136/bmj.39367.495995.ae · Cited by 1,507 · cited 1×
“Additionally, large prospective studies, including the Cancer Prevention Study II (CPS II) in the USA, and the Million Women Study in the UK reported that obesity is associated with increased cancer mortality for all cancers combined and for cancers at a number of specific sites (Tables 1 and 2) [4,5].”
ResultThe influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 3×
“pies had a higher risk of developing cancer [52].”
BackgroundStatin use and reduced cancer-related mortality
Nielsen, S. F., Nordestgaard, B. G., & Bojesen, S. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201735 · Cited by 1,030
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 1×
“Indeed in clinical trials in which plasma calcitonin levels were measured, no increase was observed with liraglutide therapy, supporting the lack of effect of GLP-1 receptor agonists on human cells [64].”
BackgroundHemkens, L. G., Grouven, U., Bender, R., Günster, C., Gutschmidt, S., Selke, G. W., & Sawicki, P. T. (2009) · Diabetologia · doi:10.1007/s00125-009-1418-4 · Cited by 607 · cited 1×
“One report suggested that it was related to higher doses of insulin [56].”
BackgroundButler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Hirsch, H. A., Iliopoulos, D., & Struhl, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221055110 · Cited by 440
Jonasson, J. M., Ljung, R., Talbäck, M., Haglund, B., Gudbjörnsdòttir, S., & Steineck, G. (2009) · Diabetologia · doi:10.1007/s00125-009-1444-2 · Cited by 412
Diabetes and breast cancer risk: A meta-analysis
Boyle, P., Boniol, M., Koechlin, A., Robertson, C., Valentini, F., Coppens, K., Fairley, L.-L., Boniol, M., Zheng, T., Zhang, Y., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.414 · Cited by 358
Cited by
Obesity and cancer risk: Emerging biological mechanisms and perspectives
Avgerinos, K. I., Spyrou, N., Mantzoros, C. S., & Dalamaga, M. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.001 · Cited by 1,567
Obesity and cancer—mechanisms underlying tumour progression and recurrence
Park, J., Morley, T. S., Kim, M., Clegg, D. J., & Scherer, P. E. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.94 · Cited by 790
Ferroni, P., Riondino, S., Buonomo, O., Palmirotta, R., Guadagni, F., & Roselli, M. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/183928 · Cited by 87
“Accordingly, the American Association of Clinical Endocrinologists and the American College of Endocrinology highlighted in a recent joint consensus report the need”
BackgroundChen, Y., Du, L., Li, L., Ma, J., Geng, X., Yao, X., Liu, G., & Sun, X. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12435 · Cited by 37
“Indirect effects of insulin on tumor cells include: (i) high levels of insulin promoting the synthesis of insulin growth factor (IGF)-1 in the liver, which then activates IGF-1 receptors expressed on tumor cells; and (ii) high levels of insulin decreasing the hepatic synthesis of IGF binding protein (IGFBP) 1 and IGFB…”
BackgroundInfluential
Metadata
- Authors
- Gallagher, E. J., & LeRoith, D.
- Venue
- Current Opinion in Endocrinology, Diabetes & Obesity
- Published
- 2013-10
- Volume
- 20
- Issue
- 5
- Pages
- 485-494
- ISSN
- 1752-296X (ISSN-L)
- OpenAlex
- W1983832091
- Cited by
- 53
- References
- 17
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetes, antihyperglycemic medications and cancer risk: smoke or fire? https://app.cochat.ai/papers/10.1097/01.med.0000433065.16918.83
- The paper
- Gallagher, E. J., & LeRoith, D. (2013). Diabetes, antihyperglycemic medications and cancer risk: smoke or fire? Current Opinion in Endocrinology, Diabetes & Obesity. https://doi.org/10.1097/01.med.0000433065.16918.83
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.